DLL3 Is a Prognostic and Potentially Predictive Biomarker for Immunotherapy Linked to PD/PD-L Axis and NOTCH1 in Pancreatic Cancer

Meeting Abstract Oncology

Tobacco Smoking-Related Mutational Signature in Classifying Smoking Associated and Non-Smoking-Associated NSCLC

Paik et Paik

JOURNAL OF THORACIC ONCOLOGY (2023)

添加到收藏夹

Article Cell Biology

Biological and immunological significance of DLL3 expression in different tumor tissues: a pan-cancer analysis

Yi Zhang et al.

Aging-US (2023)

添加到收藏夹

Article Surgery

A Combined DNA/RNA-based Next-Generation Sequencing Platform to Improve the Classification of Pancreatic Cysts and Early Detection of Pancreatic Cancer Arising From Pancreatic Cysts

Marina N. Nikiforova et al.

Summary: We developed a combined DNA/RNA sequencing platform to improve the evaluation of pancreatic cysts. The newly created genomic classifier system accurately predicted cystic precursor neoplasms and advanced neoplasia, while also increasing the sensitivity of current pancreatic cyst guidelines.

ANNALS OF SURGERY (2023)

添加到收藏夹

Review Oncology

The Notch signaling pathway: a potential target for cancer immunotherapy

Xinxin Li et al.

Summary: This article provides an overview of how Notch signaling regulates immune cells and immune responses in the tumor microenvironment, as well as strategies for targeting Notch signaling in cancer immunotherapy.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

Therapeutic Approaches in Pancreatic Cancer: Recent Updates

Lokender Kumar et al.

Summary: Cancer poses a significant challenge for effective treatment due to its complex mechanism, different stages of progression, and lack of screening and identification procedures. Pancreatic cancer, with a low survival rate of around 5 years, is ranked seventh globally among mortality-associated cancers. Therefore, it is crucial to develop diagnostic procedures for early detection, understand pancreatic cancer mechanisms, and explore therapeutic strategies. This review highlights recent developments in pancreatic cancer progression, mechanisms, and therapeutic approaches, including molecular techniques and biomedicines for effective cancer treatment.

BIOMEDICINES (2023)

添加到收藏夹

Article Urology & Nephrology

Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

Bernadett Szabados et al.

Summary: The results of the ABACUS trial showed that neoadjuvant atezolizumab in MIBC is associated with significant clinical responses and high DFS. CD8+ expression and serial ctDNA levels are correlated with outcomes and may contribute to personalized therapy in the future.

EUROPEAN UROLOGY (2022)

添加到收藏夹

Article Oncology

Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC

Wei Li et al.

Summary: This study explored the characteristics of the Notch pathway in small cell lung cancer (SCLC), clarified the expression of DLL3 in SCLC patients undergoing surgical treatment, and investigated the correlation between DLL3 expression and clinicopathological features, prognosis, and immune microenvironment. The study found that DLL3 expression was highly correlated with PD-L1 expression and Notch1 gene mutation was significantly negatively correlated with PD-L1 expression. These findings provide new insights for selecting appropriate treatment strategies for SCLC.

LUNG CANCER (2022)

添加到收藏夹

Article Oncology

Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826

Shin Nishio et al.

Summary: The study shows that pembrolizumab plus chemotherapy with or without bevacizumab can prolong progression-free survival and overall survival in patients with persistent, recurrent, or metastatic cervical cancer, and it has a manageable safety profile.

CANCER SCIENCE (2022)

添加到收藏夹

Article Oncology

Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers.

Melissa Lynne Johnson et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

DLL3 regulates Notch signaling in small cell lung cancer

Jun W. Kim et al.

Summary: This study investigates the role of tumor heterogeneity in small-cell lung cancer (SCLC) and identifies DLL3 as a biomarker of neuroendocrine state and a regulator of cell-cell interactions in SCLC.

ISCIENCE (2022)

添加到收藏夹

Article Multidisciplinary Sciences

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

Daniel J. Renouf et al.

Summary: Combining immunotherapy with chemotherapy does not improve survival in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), and can cause toxicity with elevated lymphocyte levels.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Article Oncology

Gamma Secretase Inhibitors in Cancer: A Current Perspective on Clinical Performance

Tyler R. McCaw et al.

Summary: Gamma secretase inhibitors (GSIs), originally developed as Alzheimer's therapies, have been repurposed as anticancer agents due to their ability to inhibit Notch receptor cleavage. Despite showing promise in preclinical models, GSIs have not demonstrated significant clinical benefit in most solid tumors. Further research is needed to address limitations in understanding GSI mechanisms and improve their efficacy in cancer treatment.

ONCOLOGIST (2021)

添加到收藏夹

Article Oncology

Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma A Phase 2 Randomized Clinical Trial

Davendra P. S. Sohal et al.

Summary: This study aimed to evaluate the 2-year overall survival rate of perioperative chemotherapy for resectable pancreatic ductal adenocarcinoma (PDA), but did not show significant improvement compared to historical data. The 2-year overall survival rates were 47% and 48% for the two treatment arms, demonstrating adequate safety and high resectability rates with perioperative chemotherapy, as well as challenges in quality control for resectability criteria.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Oncology

SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)

Ma A. Gomez-Espana et al.

Summary: Surgery is the potential curative therapy for both pancreatic cancer and biliary tract cancer, with adjuvant treatments like mFOLFIRINOX for PC and capecitabine for BTC improving overall survival. Neoadjuvant therapy is best for R0 resection in borderline PC, while upfront systemic chemotherapy is the treatment of choice for unresectable locally advanced PC and BTC. Promising new targets for therapy have been identified through progress in molecular biology.

CLINICAL & TRANSLATIONAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

Fiona Blackhall et al.

Summary: The study compared Rova-T and topotecan as second-line therapy in patients with SCLC expressing high levels of DLL3, showing inferior overall survival and higher rates of adverse reactions with Rova-T. This highlights the ongoing unmet therapeutic need in this population.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Pancreatic Cancer and Therapy: Role and Regulation of Cancer Stem Cells

Susmita Barman et al.

Summary: Despite advancements in clinical management, pancreatic cancer remains deadly due to late detection and high metastatic properties. Pancreatic cancer stem cells have been found to play a crucial role in tumorigenesis, progression, and chemoresistance, but targeting them effectively remains a challenge due to cancer heterogeneity and complex signaling pathways regulating PC progression.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Oncology

Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage- SCLC: Results From the Phase 3 MERU Study

Melissa L. Johnson et al.

Summary: The study evaluated the efficacy of Rova-T versus placebo as maintenance therapy in patients with extensive-stage-SCLC, but did not show a survival benefit in patients with DLL3-high tumors. Rova-T significantly improved progression-free survival versus placebo by investigator assessment, but was associated with higher grade toxicities.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Jong-Mu Sun et al.

Summary: This study aimed to evaluate the antitumor activity of pembrolizumab plus chemotherapy versus chemotherapy alone as first-line treatment in advanced esophageal cancer. Results showed that pembrolizumab plus chemotherapy significantly improved overall survival and progression-free survival in patients with esophageal squamous cell carcinoma.

LANCET (2021)

添加到收藏夹

Article Oncology

Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden

Filippo Pietrantonio et al.

ONCOLOGIST (2020)

添加到收藏夹

Article Oncology

A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer

Susanne Hipp et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Oncology

Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth

Xin Chen et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortes et al.

LANCET (2020)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony S. K. Mok et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Delta-like 3 localizes to neuroendocrine cells and plays a pivotal role in gastrointestinal neuroendocrine malignancy

Kentaro Matsuo et al.

CANCER SCIENCE (2019)

添加到收藏夹

Article Oncology

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

Daniel Morgensztern et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2018)

添加到收藏夹

Review Pharmacology & Pharmacy

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate

Bilal H. Lashari et al.

DRUGS IN R&D (2018)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

P. Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

T. Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Gastroenterology & Hepatology

Immunotherapy for pancreatic cancer: Barriers and breakthroughs

Robert J. Torphy et al.

ANNALS OF GASTROENTEROLOGICAL SURGERY (2018)

添加到收藏夹

Article Medicine, General & Internal

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

John P. Neoptolemos et al.

LANCET (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer

Jing Shan Lim et al.

NATURE (2017)

添加到收藏夹

Article Surgery

Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for Tand N Staging in Patients With Pancreatic Adenocarcinoma

Peter J. Allen et al.

ANNALS OF SURGERY (2017)

添加到收藏夹

Article Oncology

More deaths from pancreatic cancer than breast cancer in the EU by 2017

J. Ferlay et al.

ACTA ONCOLOGICA (2016)

添加到收藏夹

Article Oncology

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro

M. Ducreux et al.

ANNALS OF ONCOLOGY (2015)

添加到收藏夹

Review Oncology

Pathological and Molecular Evaluation of Pancreatic Neoplasms

Arvind Rishi et al.

SEMINARS IN ONCOLOGY (2015)

添加到收藏夹

Article Oncology

A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma

Ana De Jesus-Acosta et al.

INVESTIGATIONAL NEW DRUGS (2014)

添加到收藏夹

Review Oncology

Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis

Wei-Chih Liao et al.

LANCET ONCOLOGY (2013)

添加到收藏夹

Article Medicine, General & Internal

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

Jianjiong Gao et al.

SCIENCE SIGNALING (2013)

添加到收藏夹

Article Oncology

The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models

Masamichi Mizuma et al.

MOLECULAR CANCER THERAPEUTICS (2012)

添加到收藏夹

Editorial Material Oncology

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data

Ethan Cerami et al.

CANCER DISCOVERY (2012)

添加到收藏夹

Article Oncology

Ligand-dependent Notch Signaling Is Involved in Tumor Initiation and Tumor Maintenance in Pancreatic Cancer

Michael E. Mullendore et al.

CLINICAL CANCER RESEARCH (2009)

添加到收藏夹

Article Gastroenterology & Hepatology

Inhibition of γ-Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal Adenocarcinoma

Ruben Plentz et al.

GASTROENTEROLOGY (2009)

添加到收藏夹

Review Oncology

Significance of Cellular Senescence in Aging and Cancer

Angela Grimes et al.

CANCER RESEARCH AND TREATMENT (2009)

添加到收藏夹

Review Immunology

PD-1 and its ligands in tolerance and immunity

Mary E. Keir et al.

ANNUAL REVIEW OF IMMUNOLOGY (2008)

添加到收藏夹

Article Cell Biology

Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo

Insa Geffers et al.

JOURNAL OF CELL BIOLOGY (2007)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial

Helmut Oettle et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)

添加到收藏夹

Article Multidisciplinary Sciences

Notch signaling controls multiple steps of pancreatic differentiation

LC Murtaugh et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)

添加到收藏夹

DLL3 Is a Prognostic and Potentially Predictive Biomarker for Immunotherapy Linked to PD/PD-L Axis and NOTCH1 in Pancreatic Cancer

相关参考文献

导出引文

分享论文